

MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	(unaudited) <u>Mar. 31, 2001</u>	(unaudited) <u>Mar. 31, 2000</u>	(unaudited) <u>Mar. 31, 2001</u>	(unaudited) <u>Mar. 31, 2000</u>
REVENUES:				
Research revenue	\$6,652,289	\$7,287,880	\$22,409,558	\$18,791,397
Predictive medicine revenue	4,914,950	2,426,886	11,930,856	6,065,043
Total revenues	<u>11,567,239</u>	<u>9,714,766</u>	<u>34,340,414</u>	<u>24,856,440</u>
COSTS AND EXPENSES:				
Predictive medicine cost of revenue	2,149,029	1,068,511	5,181,389	2,860,598
Research and development expense	8,428,402	8,333,149	26,570,236	20,325,418
Selling, general and administrative expense	4,247,554	3,337,482	12,271,188	9,713,413
Total costs and expenses	<u>14,824,985</u>	<u>12,739,142</u>	<u>44,022,813</u>	<u>32,899,429</u>
Operating loss	<u>(3,257,746)</u>	<u>(3,024,376)</u>	<u>(9,682,399)</u>	<u>(8,042,989)</u>
Other income (expense):				
Interest income	2,057,167	949,162	5,477,560	2,259,615
Other	(27,465)	(14,670)	(283,113)	(374,752)
Net loss before taxes	<u>(1,228,044)</u>	<u>(2,089,884)</u>	<u>(4,487,952)</u>	<u>(6,158,126)</u>
Income taxes	500,000	-	500,000	-
Net loss	<u>(\$1,728,044)</u>	<u>(\$2,089,884)</u>	<u>(\$4,987,952)</u>	<u>(\$6,158,126)</u>
Basic and diluted loss per share	<u>(\$0.07)</u>	<u>(\$0.10)</u>	<u>(\$0.22)</u>	<u>(\$0.31)</u>
Basic and diluted weighted average shares outstanding	<u>23,219,841</u>	<u>20,682,538</u>	<u>22,646,020</u>	<u>19,929,208</u>

SELECTED BALANCE SHEET DATA

	<u>Mar. 31, 2001</u>	<u>June 30, 2000</u>
Cash and investments	\$140,831,407	\$88,655,844
Total assets	\$162,245,219	\$106,375,305
Shareholders' equity	\$139,231,369	\$77,706,647